Premium
Inositol may worsin attention deficit disorder with hyperactivity
Author(s) -
Levine Joseph,
Ring Aliza,
Barak Yoram,
Elizur Avner,
Belmaker R. H.
Publication year - 1995
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470100608
Subject(s) - inositol , placebo , phosphatidylinositol , antidepressant , second messenger system , depression (economics) , placebo controlled study , endocrinology , medicine , pharmacology , receptor , psychology , chemistry , double blind , biochemistry , kinase , pathology , alternative medicine , hippocampus , economics , macroeconomics
Antidepressant drugs have been reported to improve ADDH symtomatology. Myoinositol is a simple isomer of glucose and is the precursor of the phosphatidylinositol second messenger system in brain. Both α 1 ‐adrenergic and 5HT 2 receptors activate this second messenger system. Recently, we found inositol to be effective in depression. Therefore we decided to evaluate the effects of oral inositol in children with ADDH in a double‐blind, cross‐over, placebo‐controlled manner. Eleven children, mean age 8.9 ± 3.6 years with a mean illness duration of 4.5 ± 2.8 years were enrolled in an 8‐week trial. Inositol or dextrose (placebo) was dispensed in powder form at a dose of 200 mg/kg aggravation of the syndrome with myo‐inositol as compared to placebo.